The latest tempest over a dramatic drug price hike riles two powerful senators — who can’t actually do anything about it

First Nostrum CEO Nirmal Mulye caught the attention of FDA commissioner Scott Gottlieb when he jacked up the price of an old antibiotic from $474.75 to $2,392 last month. Now he has a pair of angry US senators on the warpath over his controversial, Martin Shkreli-like comments about the “moral requirement” of earning money for his investors and comparing the move to pricing art.